NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

非小細胞肺癌 (NSCLC):流行病學預測 (∼2029年)

Non-Small Cell Lung Cancer - Epidemiology Forecast to 2029

出版商 GlobalData 商品編碼 979399
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
非小細胞肺癌 (NSCLC):流行病學預測 (∼2029年) Non-Small Cell Lung Cancer - Epidemiology Forecast to 2029
出版日期: 2020年12月31日內容資訊: 英文 58 Pages
簡介

全球主要8個國家非小細胞肺癌 (NSCLC)的18歲以上的診斷病例數,2019年顯示了79萬4999個案例。各地區中,中國都市區以301,036案例佔最大的佔有率,西班牙以29,977案例顯示最小的佔有率。還有預計在預測期間中以3.01%的年複合成長率發展,2029年的診斷病例數增加到103萬4554個案例。

本報告提供全球主要8個國家非小細胞肺癌 (NSCLC)的市場調查,疾病概要,病因、病理生理學,發病數的變化、預測,各種區分的明細,未來展望等資料彙整。

第1章 目錄

第2章 摘要整理

第3章 流行病學

  • 疾病的背景
  • 危險因素、合併症
  • 世界的趨勢、歷史的趨勢
  • 預測調查手法
  • 流行病學預測
    • 診斷病例數
    • 診斷病例數:男女
    • 診斷病例數:各年齡
    • 診斷病例數:各階段
    • 診斷病例數:各組織型
    • 診斷病例數:各基因生物標誌物、EGFR、KRAS變異
    • 診斷病例數:各變異
    • 5年確診患者數
  • 討論

第4章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER262-20

Non-Small Cell Lung Cancer - Epidemiology Forecast to 2029

Lung cancer is a disease of uncontrolled cell growth in the lung tissues. It is one of the most commonly occurring cancers in the world (International Agency for Research on Cancer, 2018). There are two main types of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Other less common types of lung tumors include lung carcinoid tumors, adenoid cystic carcinomas, lymphomas, and sarcomas. Benign lung tumors such as hamartomas are rare. NSCLC is the most common type of lung cancer, making up about 85% of all lung cancers. SCLC accounts for 10-15% of lung cancers, while carcinoid tumors are the rarest, occurring in fewer than five percent of lung cancers (American Cancer Society, 2016). The majority of lung cancer cases are attributable to smoking. However, a sizable portion of cases occur in non-smokers, implying that genetic components, family history, and environmental exposure also play a prominent role in the development of the disease (American Cancer Society, 2016).

In 2019, there were 794,999 diagnosed incident cases of NSCLC in men and women combined, ages 18 years and older, in the 8MM. Urban China accounted for the largest share of these cases with 301,036 diagnosed incident cases, while Spain accounted for the smallest share with 29,977 cases in 2019. GlobalData epidemiologists forecast an increase in the diagnosed incident cases of NSCLC to 1,034,554 cases in 2029 in the 8MM at an Annual Growth Rate (AGR) of 3.01% during the forecast period. In 2019, there were 1,060,302 five-year diagnosed prevalent cases of NSCLC in men and women combined, ages 18 years and older, in the 8MM. Urban China accounted for the largest share of these cases with 354,667 cases, while Spain accounted for the smallest share with 25,831 cases in 2019. The five-year diagnosed prevalent cases of NSCLC will increase to 1,370,422 cases in 2029 at an AGR of 2.92% during the forecast period.

Scope

  • The Non-Small Cell Lung Cancer (NSCLC) Epidemiology Report provides an overview of the risk factors and the global and historical trends for NSCLC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). The report includes diagnosed incident cases and five-year diagnosed prevalent cases of NSCLC in these markets from 2019-2029.
  • The incident cases are further segmented by sex and age (18-39 years, 40-59 years, 60-79 years, and 80 years and older), by cancer stage at diagnosis (stages IA, IB, IIA, IIB, IIIA, IIIB, IIIC, and IV), and by cancer histology subtype (non-squamous cell carcinoma [adenocarcinoma, large cell carcinoma, and others] and squamous cell carcinoma). Diagnosed incident cases of non-squamous cell carcinoma are further segmented by mutations, specifically immunotherapy biomarkers, and genomic biomarkers. Diagnosed incident cases of non-squamous cell carcinoma EGFR are segmented by subtypes. Diagnosed incident cases of non-squamous cell carcinoma KRAS were segmented by subtypes. The diagnosed incident cases of squamous cell carcinoma are segmented by mutations.
  • The NSCLC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The NSCLC Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global NSCLC market.
  • Quantify patient populations in the global NSCLC market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for NSCLC therapeutics in each of the markets covered.
  • Understand magnitude of NSCLC by stage at diagnosis, histology types, and biomarkers.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Non-Small Cell Lung Cancer: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
    • 3.4.3 Diagnosed Incident Cases of NSCLC
    • 3.4.4 Diagnosed Incident Cases of NSCLC by Stage at Diagnosis
    • 3.4.5 Diagnosed Incident Cases of NSCLC by Histological Types
    • 3.4.6 Mutations Among Diagnosed Incident Cases of Non-Squamous Cell Carcinoma and Squamous Cell Carcinoma
    • 3.4.7 Five-Year Diagnosed Prevalent Cases of NSCLC
  • 3.5 Epidemiological Forecast for NSCLC, 2019-2029
    • 3.5.1 Diagnosed Incident Cases of NSCLC
    • 3.5.2 Sex-Specific Diagnosed Incident Cases of NSCLC
    • 3.5.3 Age-Specific Diagnosed Incident Cases of NSCLC
    • 3.5.4 Diagnosed Incident Cases of NSCLC by Stage at Diagnosis
    • 3.5.5 Diagnosed Incident Cases of NSCLC by Histological Type
    • 3.5.6 Diagnosed Incident Cases of Non-Squamous Cell Carcinoma by Mutations: Genomic Biomarkers, EGFR and KRAS Mutations
    • 3.5.7 Diagnosed Incident Cases of Squamous Cell Carcinoma by Mutations
    • 3.5.8 Five-Year Diagnosed Prevalent Cases of NSCLC
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 COVID-19 Impact
    • 3.6.3 Limitations of the Analysis
    • 3.6.4 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer

List of Tables

List of Tables

  • Table 1: Summary of Newly Added Data Types and Countries
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities for NSCLC
  • Table 4: 8MM, Diagnosed Incident Cases of NSCLC by Stage at Diagnosis, Ages ≥18 Years, Both Sexes, N, 2019
  • Table 5: 8MM, Diagnosed Incident Cases of Non-Squamous Cell Carcinoma by Immunotherapy and Genomic Biomarkers, Ages ≥18 Years, Both Sexes, N, 2019
  • Table 6: 8MM, Diagnosed Incident Cases of Squamous Cell Carcinoma by Mutations, Ages ≥18 Years, Both Sexes, N, 2019

List of Figures

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of NSCLC, Both Sexes, Ages ≥18 Years, N, 2019 and 2029
  • Figure 2: 8MM, Five-Year Diagnosed Prevalent Cases of NSCLC, Both Sexes, Ages ≥18 Years, N, 2019 and 2029
  • Figure 3: 8MM, Diagnosed Incidence of